Neurotransmitter-based strategies for the treatment of cognitive dysfunction in Down syndrome
- 1 October 2014
- journal article
- review article
- Published by Elsevier BV in Progress in Neuro-Psychopharmacology and Biological Psychiatry
- Vol. 54, 140-148
- https://doi.org/10.1016/j.pnpbp.2014.05.004
Abstract
No abstract availableKeywords
Funding Information
- Down Syndrome Research and Treatment Foundation
- Research Down Syndrome
- Alzheimer Association
- Arkansas State University
This publication has 100 references indexed in Scilit:
- Pharmacotherapy with Fluoxetine Restores Functional Connectivity from the Dentate Gyrus to Field CA3 in the Ts65Dn Mouse Model of Down SyndromePLOS ONE, 2013
- Comprehensive behavioral phenotyping of Ts65Dn mouse model of Down Syndrome: Activation of β1-adrenergic receptor by xamoterol as a potential cognitive enhancerNeurobiology of Disease, 2011
- The cholinergic system in aging and neuronal degenerationBehavioural Brain Research, 2011
- Effects of long-term memantine on memory and neuropathology in Ts65Dn mice, a model for Down syndromeBehavioural Brain Research, 2011
- Olig1 and Olig2 triplication causes developmental brain defects in Down syndromeNature Neuroscience, 2010
- Epilepsy and Cognitive Impairments in Alzheimer DiseaseArchives of Neurology, 2009
- Neuroprotective effects of brain-derived neurotrophic factor in rodent and primate models of Alzheimer's diseaseNature Medicine, 2009
- Effects of Memantine on Neuronal Structure and Conditioned Fear in the Tg2576 Mouse Model of Alzheimer's DiseaseNeuropsychopharmacology, 2008
- Neuroimaging of individuals with Down’s syndrome at-risk for dementia: Evidence for possible compensatory eventsNeuroImage, 2008
- Plasma amino acids and neopterin in healthy persons with Down’s syndromeJournal of Neural Transmission, 2007